Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 1;9(4):e003491.
doi: 10.1136/rmdopen-2023-003491.

Increased mortality in patients with RA-associated interstitial lung disease: data from a French administrative healthcare database

Pierre-Antoine Juge  1   2 , Lidwine Wemeau  3 , Sebastien Ottaviani  4 , Guillaume Desjeux  5 , Joe Zhuo  6 , Virginie Vannier-Moreau  7 , René-Marc Flipo  8 , Bruno Crestani  9 , Philippe Dieudé  4   2
Affiliations

Increased mortality in patients with RA-associated interstitial lung disease: data from a French administrative healthcare database

Pierre-Antoine Juge et al. RMD Open. .

Erratum in

Abstract

Objectives: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). The objectives of this study were to estimate mortality rate in patients with RA-ILD and identify factors affecting mortality.

Methods: Data from a French national claims database (Système National des Données de Santé) from 2013 to 2018 were analysed. Adults with an RA diagnosis (International Classification of Diseases (ICD)-10 codes M05, M06.0, M06.8 and M06.9) were included. ILD diagnosis was defined with ICD-10 code J84. Mortality rates were compared between patients with RA with and without ILD, using Cox proportional hazards regression, after matching 1:1 for age, sex, age at RA-ILD onset and RA duration.

Results: Among 173 132 patients with RA, 4330 (3%) also had ILD (RA-ILD). After matching, RA-ILD was associated with an increased mortality rate (HR 3.4, 95% CI 3.1 to 3.9). The HR for mortality was greater for: patients aged <75 years (HR 4.8, 95% CI 3.9 to 5.9) versus ≥75 years (HR 3.0, 95% CI 2.6 to 3.5); patients with ILD onset occurring before RA onset (HR 8.4, 95% CI 5.5 to 13.0) versus ILD onset occurring after RA onset (HR 2.9, 95% CI 2.6 to 3.3); and men (HR 5.2, 95% CI 4.4 to 6.2) versus women (HR 3.6, 95% CI 3.0 to 4.2).

Conclusion: In this nationwide cohort study, RA-ILD was associated with increased mortality rate (vs in patients with RA without ILD), notably for those aged <75 years, those whose ILD preceded RA onset and men.

Keywords: arthritis, rheumatoid; epidemiology; interstitial lung disease.

PubMed Disclaimer

Conflict of interest statement

Competing interests: PA-J has received grant/research support from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Medac, Novartis, Roche Chugai and Societe Francaise de Rhumatologie; and consultancy fees from Bristol Myers Squibb. LW has received consultancy fees from Boehringer Ingelheim, Bristol Myers Squibb, Roche and Sanofi. SO has received consultancy fees from AbbVie, Bristol Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novartis, Roche-Chugai, SOBI and UCB. GD has received consultancy fees from Bristol Myers Squibb. JZ and VV-M are employees of and shareholders in Bristol Myers Squibb. R-MF has received speakers bureau fees from AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Medac, Merck Sharp & Dohme, Novartis, Pfizer and Roche-Chugai; and grant/research support from Amgen, Janssen, Novartis and Pfizer. BC has received consultancy fees from Apellis, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Roche and Sanofi; and grant/research support from Boehringer Ingelheim, Bristol Myers Squibb and Roche. PD has received consultancy fees from Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Eli Lilly, Medac, Novartis, Pfizer and Sanofi; and grant/research support from Bristol Myers Squibb, GlaxoSmithKline and Pfizer.

Figures

Figure 1
Figure 1
Survival in patients with RA-ILD versus RA-noILD in the matched population. ILD, interstitial lung disease; RA, rheumatoid arthritis; RA-ILD, RA with ILD; RA-noILD, RA without ILD.
Figure 2
Figure 2
Forest plot showing HR for mortality in patients with RA-ILD compared with patients with RA-noILD. ILD, interstitial lung disease; RA, rheumatoid arthritis; RA-ILD, RA with ILD; RA-noILD, RA without ILD.
See this image and copyright information in PMC

References

    1. Almutairi K, Nossent J, Preen D, et al. . The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int 2021;41:863–77. 10.1007/s00296-020-04731-0 - DOI - PubMed
    1. Duarte AC, Porter JC, Leandro MJ. The lung in a cohort of rheumatoid arthritis patients-an overview of different types of involvement and treatment. Rheumatology (Oxford) 2019;58:2031–8. 10.1093/rheumatology/kez177 - DOI - PubMed
    1. Turesson C, O’Fallon WM, Crowson CS, et al. . Extra-Articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003;62:722–7. 10.1136/ard.62.8.722 - DOI - PMC - PubMed
    1. Gabbay E, Tarala R, Will R, et al. . Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 1997;156:528–35. 10.1164/ajrccm.156.2.9609016 - DOI - PubMed
    1. Habib HM, Eisa AA, Arafat WR, et al. . Pulmonary involvement in early rheumatoid arthritis patients. Clin Rheumatol 2011;30:217–21. 10.1007/s10067-010-1492-5 - DOI - PubMed